CareDx (NASDAQ:CDNA) Announces Quarterly Earnings Results

CareDx (NASDAQ:CDNA) issued its quarterly earnings data on Thursday. The company reported $0.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $0.15, FiscalAI reports. The firm had revenue of $131.95 million during the quarter, compared to the consensus estimate of $113.83 million. CareDx had a negative return on equity of 2.65% and a negative net margin of 2.01%.The business’s revenue for the quarter was up 52.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.16) EPS.

Here are the key takeaways from CareDx’s conference call:

• Q2 revenue rose 52% to $132 million, while testing services revenue increased 61% to $100 million and adjusted EBITDA reached $25 million, or 19% of revenue. The company also ended the quarter with $374 million in cash and no debt.
• CareDx raised its 2026 guidance to $490 million–$500 million in revenue and $66 million–$78 million in adjusted EBITDA, including $24 million of second-half specialty oncology revenue and 258,000–266,000 tests for the year.
• Transplant testing growth remains strong, with Q2 volume up 17% to 58,000 tests as both surveillance and for-cause use expanded. Management cited broader clinical adoption, improved workflows, and evidence supporting AlloSure’s use in risk assessment and treatment monitoring.
• The company reported progress across its growth pipeline and NavDx acquisition, including a planned 2027 AlloHeme commercial launch, a 2026 clinical-study launch for HistoMap Kidney, and integration initiatives intended to expand NavDx adoption and improve reimbursement and workflow efficiency.
• Management characterized its outlook as prudent while it integrates NavDx billing and operating systems; specialty oncology is currently modeled at roughly 63% gross margin and may require additional investment, although CareDx continues to target approximately 20% long-term adjusted EBITDA margins.

CareDx Price Performance

Shares of CDNA stock traded up $5.24 on Friday, reaching $43.34. 1,517,115 shares of the stock were exchanged, compared to its average volume of 807,617. CareDx has a one year low of $11.26 and a one year high of $44.56. The stock has a market cap of $2.24 billion, a PE ratio of -269.21 and a beta of 2.43. The stock has a 50 day moving average price of $28.15 and a 200 day moving average price of $22.46.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on CDNA shares. BTIG Research raised their target price on CareDx from $28.00 to $45.00 and gave the company a “buy” rating in a research note on Thursday, July 16th. William Blair raised shares of CareDx to a “hold” rating in a report on Thursday, July 16th. Wall Street Zen raised shares of CareDx from a “buy” rating to a “strong-buy” rating in a report on Sunday, May 3rd. Weiss Ratings cut shares of CareDx from a “sell (d+)” rating to a “sell (d)” rating in a research report on Wednesday, July 15th. Finally, Craig Hallum reiterated a “hold” rating and set a $35.00 target price on shares of CareDx in a research report on Thursday, July 16th. One investment analyst has rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $36.75.

Insider Activity

In other CareDx news, Director Hannah Valantine sold 12,103 shares of the business’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $23.11, for a total transaction of $279,700.33. Following the completion of the sale, the director directly owned 36,686 shares of the company’s stock, valued at approximately $847,813.46. The trade was a 24.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John Walter Hanna, Jr. sold 39,900 shares of the company’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $29.24, for a total transaction of $1,166,676.00. Following the transaction, the chief executive officer owned 661,959 shares in the company, valued at approximately $19,355,681.16. The trade was a 5.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 78,936 shares of company stock worth $2,093,708. 2.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On CareDx

Several institutional investors have recently modified their holdings of the business. Quarry LP acquired a new position in CareDx in the fourth quarter valued at approximately $25,000. Meeder Asset Management Inc. acquired a new stake in CareDx during the 4th quarter worth $79,000. Quantbot Technologies LP acquired a new stake in CareDx during the 3rd quarter worth $89,000. Tower Research Capital LLC TRC raised its position in shares of CareDx by 120.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,608 shares of the company’s stock valued at $149,000 after acquiring an additional 4,160 shares during the last quarter. Finally, State of Wyoming bought a new stake in shares of CareDx during the 4th quarter valued at $155,000.

Key CareDx News

Here are the key news stories impacting CareDx this week:

• Positive Sentiment: CareDx reported second-quarter earnings of $0.37 per share, well above the consensus estimate of $0.22 and up from a loss of $0.16 per share in the year-earlier period. CareDx Announces Second Quarter 2026 Financial Results
• Positive Sentiment: Revenue increased 52.2% year over year to $131.95 million, exceeding analysts’ $113.83 million forecast. The strong top-line performance supports investor confidence in demand for CareDx’s transplant-monitoring and diagnostic services. CareDx Q2 Non-GAAP Earnings, Revenue Rise; Lifts 2026 Revenue Outlook
• Positive Sentiment: The company raised its 2026 revenue outlook to $490 million-$500 million, substantially above the current analyst consensus of approximately $455.7 million. The improved guidance suggests management expects recent growth trends to continue through the remainder of the year. CareDx Beats Q2 Earnings and Revenue Estimates
• Neutral Sentiment: The earnings release and conference call provided additional detail on the outlook, but investors will focus on whether CareDx can convert its rapid revenue growth into consistent profitability. CareDx Q2 2026 Earnings Call Transcript
• Negative Sentiment: Despite the adjusted earnings beat, CareDx reported a negative net margin of 2.01% and negative return on equity of 2.65%, indicating that bottom-line profitability remains a risk. The stock’s high beta and valuation near its 52-week high may also increase volatility if execution slows.

CareDx Company Profile

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non?invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post?transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor?derived cell?free DNA assay used primarily in kidney transplant monitoring.